Condition
Glioma, Astrocytic
Total Trials
5
Recruiting
2
Active
3
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (3)
Trial Status
Recruiting2
Completed1
Active Not Recruiting1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01837862Phase 1Active Not Recruiting
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
NCT05532397Not ApplicableRecruitingPrimary
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
NCT02549833Phase 1Completed
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
NCT06572475Not ApplicableRecruiting
USPIO Enhanced MR Imaging in CNS Tumours (UMIC)
NCT02924038Phase 1Terminated
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Showing all 5 trials